We are recruiting women with stage 0-III estrogen positive breast cancer who are taking aromatase inhibitors. This study is done to better understand the role of the gut microbiome (e.g., bacteria, fungi, and other microbes living in the human gastrointestinal tract) and diet in protecting against and/or predisposing to musculoskeletal symptoms (e.g., joint pain or stiffness, bone pain, etc.) in breast cancer survivors receiving aromatase inhibitors. This study was approved by the UConn Health IRB, Protocol #22-199S-1.

 

 

Who is eligible?

• Currently taking aromatase inhibitors, including anastrozole (Arimidex),      letrozole (Femara), and exemestane (Aromasin), etc.
• Ages 30-79 years
• Willing to complete questionnaires about pain, diet, and lifestyle, and provide saliva and at-home stool samples
• No diagnosed chronic gastrointestinal tract disorders (e.g., irritable bowel syndrome, Crohn’s disease, ulcerative colitis, etc.)
• Able to speak and read English

 

All participants will receive up to $100 upon completion of the study ($80 for completing surveys and providing a saliva sample, an additional $20 for submitting of a stool sample).

This study is available remotely. You may also visit the UConn School of Nursing Biobehvioral Lab on the Storrs or Farmington campus.

If you are interested, please complete the link: https://uchredcap.uchc.edu/redcap/surveys/?s=8YCJALJAJCL8RTK8 

 

You may learn more on study site at https://bbl.nursing.uconn.edu/aimic-study/. 

 

For more information, contact: the study PI at yanglab@uconn.edu (Tel: 860-341- 1778)